We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.4B
AUM Growth
-$236M
Cap. Flow
-$395M
Cap. Flow %
-16.46%
Top 10 Hldgs %
48.89%
Holding
97
New
20
Increased
44
Reduced
26
Closed
6

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$85.4M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$45.1M
3
MRK icon
Merck
MRK
+$36.1M
4
EW icon
Edwards Lifesciences
EW
+$21.1M
5
CMRX
Chimerix, Inc.
CMRX
+$19M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$80.2M
2
AGN
Allergan plc
AGN
+$63.6M
3
VTRS icon
Viatris
VTRS
+$58.6M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$54.9M
5
KERX
Keryx Biopharmaceuticals Inc
KERX
+$48.7M

Sector Composition

Rank Sector Weight
1 Healthcare 91.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
76
Boston Scientific
BSX
$67.6B
$33K ﹤0.01%
+1,870
New +$33.4K
BDX icon
77
Becton Dickinson
BDX
$43.8B
$30K ﹤0.01%
+215
New +$29.7K
ZBH icon
78
Zimmer Biomet
ZBH
$17.8B
$27K ﹤0.01%
+252
New +$27.9K
BAX icon
79
Baxter International
BAX
$12.1B
$22K ﹤0.01%
+580
New +$21.7K
STJ
80
DELISTED
St Jude Medical
STJ
$22K ﹤0.01%
+305
New +$22K
ARAY icon
81
Accuray
ARAY
$26.8M
$16K ﹤0.01%
2,395
-224,800
-99% -$1.67M
ENTL
82
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$13K ﹤0.01%
+505
New +$12.8K
THOR
83
DELISTED
THORATEC CORPORATION
THOR
$11K ﹤0.01%
+250
New +$10.9K
VAR
84
DELISTED
Varian Medical Systems, Inc.
VAR
$10K ﹤0.01%
+131
New +$10.3K
TRNX
85
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$10K ﹤0.01%
+395
New +$10.3K
HOLX
86
DELISTED
Hologic
HOLX
$9K ﹤0.01%
+225
New +$7.88K
XENT
87
DELISTED
Intersect ENT, Inc
XENT
$9K ﹤0.01%
+320
New +$8.39K
CSII
88
DELISTED
Cardiovascular Systems, Inc.
CSII
$8K ﹤0.01%
+285
New +$9.21K
TNDM icon
89
Tandem Diabetes Care
TNDM
$1.18B
$7K ﹤0.01%
65
-11,077
-99% -$1.38M
IART icon
90
Integra LifeSciences
IART
$1.52B
$6K ﹤0.01%
+232
New +$6.18K
SPNC
91
DELISTED
Spectranetics Corp
SPNC
$5K ﹤0.01%
+230
New +$6.42K
CARM
92
DELISTED
Carisma Therapeutics
CARM
– –
-5,624
Closed -$1M
ADXS
93
DELISTED
Advaxis Inc
ADXS
– –
-10,044
Closed -$2.17M
KERX
94
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-3,825,256
Closed -$48.7M
WX
95
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
– –
-40,653
Closed -$1.58M
GEVA
96
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-365,684
Closed -$35.7M
MDVN
97
DELISTED
MEDIVATION, INC.
MDVN
– –
-417,778
Closed -$27M
1 2 3
4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sectoral Asset Management held 97 positions worth $2.4B, down 9% from $2.63B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sectoral Asset Management withdrew a net $395M in Q2 2015, closing 6 positions and reducing 26 holdings. Its most notable exit was Keryx Biopharmaceuticals Inc, an estimated $48.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Regeneron Pharmaceuticals worth $89.2M.

  • Sectoral Asset Management's largest Q2 2015 buy was Regeneron Pharmaceuticals: 174,900 shares worth $89.2M.
  • Sectoral Asset Management added most to Alexion Pharmaceuticals in Q2 2015, an estimated $45.1M increase.
  • Sectoral Asset Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $80.2M.
  • Sectoral Asset Management fully exited Keryx Biopharmaceuticals Inc in Q2 2015, selling an estimated $48.7M.
  • Sectoral Asset Management's ten largest holdings make up 49% of its $2.4B portfolio in Q2 2015.
  • Sectoral Asset Management opened 20 new positions and closed 6 in Q2 2015.
  • Sectoral Asset Management's portfolio value fell 9% quarter-over-quarter to $2.4B.

Based on Sectoral Asset Management's 13F filing for Q2 2015, filed 13 Aug 2015.